Tokyo, Japan―Tosoh Corporation is developing a test reagent to detect antibodies related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the strain of coronavirus responsible for the novel coronavirus disease 2019, or COVID-19. The company is striving for a rapid, high-sensitivity reagent based on unique single test cup and lyophilizing technology characteristic of the company’s immunoassay test reagents, specifically for its AIA-CL series of fully automated chemiluminescence enzyme immunoassay analyzer. The company aims for a simple, high-throughput means of detecting anti-SARS-CoV-2 antibodies utilizing the AIA-CL series analyzers in combination with the reagent it has under development.
To date, Tosoh has developed fully automated immunoassay test systems characterized by a proprietary single test cup, and provided more than 60 tests menus worldwide. It is working to complete development of the new reagent at the earliest possible date by leveraging its accumulated technologies and know-how. It is joined in this effort by Yokohama City University and Kanto Chemical Co., Inc.
Research from two professors underpins the joint effort to develop a test reagent to detect anti-SARS-CoV-2 antibodies on the fully automated chemiluminescence enzyme immunoassay analyzers. The work of a research team led by Akihide Ryo, a professor in the Microbiology Department of Yokohama City University’s Association of Medical Science resulted in an antivirus antibody detection method. And a report issued from a professor and principal researcher Takeharu Yamanaka of the Biostatistics Department of the Association of Medical Science at Yokohama City University titled, “Development of fully automated high-throughput immunodiagnostic system for novel coronavirus antibody detection and research toward making this detection system available to the public,” which was adopted by the Japan Agency for Medical Research and Development (AMED) as part of its research projects as countermeasures against infectious diseases such as viruses for fiscal 2020.
Tosoh, meanwhile, also continues to pursue the development of a viral genetic test kit for the novel coronavirus. It employs the transcription reverse transcription concerted (TRC) reaction method. The company’s aim is to take it to market as an in vitro diagnostic medical device. Tosoh has called for the cooperation of various concerned parties with the aim of making it available as early as possible as a countermeasure against the global public health issue caused by the novel coronavirus.
Notes:
- With regard to AMED’s research projects as countermeasures against infectious diseases such as viruses for fiscal 2020, given the global outbreak of the novel coronavirus disease 2019(COVID-19) and the high expectations for use in simple, rapid and decentralized virus testing, systems to prevent the spread of infection, and the development of therapeutic equipment for critically ill patients, this project is being undertaken to support the implementation of R&D activities leading to resolving the infection issue and the development and demonstration of devices and systems meeting on-site needs for novel coronavirus disease countermeasures.
- The Ministry of Economy, Trade and Industry’s fiscal 2020 supplementary budget supports the development of technologies as countermeasures to infectious diseases such as viruses. The supplementary budget aims to make medical devices and systems available to the public as countermeasures to infectious diseases such as the novel coronavirus. This project will support the implementation of R&D activities leading to resolving the infection issue and the development and demonstration of devices and systems meeting on-site needs for novel coronavirus disease countermeasures.
For more information on Tosoh’s automated immunoassay analysers (AIA), please visit:
www.diagnostics.eu.tosohbioscience.com/our-products/immunoassay-analyzers »
TOSOH CORPORATION
WHO WE ARE
Tosoh Corporation is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people and generated net sales of ¥786.1 billion (US$7.2 billion at the average rate of ¥108.7 to the US dollar) in fiscal 2020, ended March 31, 2020.
WHAT WE DO
Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh’s petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future in part by manufacturing a variety of eco-products.
Stock Exchange Ticker Symbol: 4042
DISCLAIMER
This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. Forward-looking statements are identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the results expressed in forward-looking statements.